Phase 3 EVER-002 trial is out
Paolo Tarantino shared an article by Binghe Xu on X:
“Phase 3 EVER-002 trial (also known as TROPics02 in Asian patients) out in Nature Medicine.
Consistent with TROPics, SG improved PFS & OS over chemotherapy in HR+/HER2- MBC, with a small PFS delta but with a meaningful OS delta (~5 mo).
Same OS benefit irrespective of Trop2 experiment.”
Authors: Binghe Xu, Shusen Wang, Min Yan, Joohyuk Sohn, Wei Li, Jinhai Tang, Xiaojia Wang, Ying Wang, Seock-Ah Im, Dongdong Jiang, Theresa Valdez, Anandaroop Dasgupta, Yiran Zhang, Yilin Yan, Kimberly M. Komatsubara, Wei-Pang Chung, Fei Ma and Ming-Shen Dai
Source: Paolo Tarantino/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023